Published in Biochim Biophys Acta on November 01, 2012
Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis Rheumatol (2015) 1.40
S100 proteins in cancer. Nat Rev Cancer (2015) 1.35
Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat (2013) 1.04
Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res (2013) 1.02
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother (2014) 0.97
Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. J Exp Med (2015) 0.96
ID1 promotes breast cancer metastasis by S100A9 regulation. Mol Cancer Res (2014) 0.92
Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget (2015) 0.84
Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9. Oncotarget (2015) 0.83
Proteomic analysis of stromal proteins in different stages of colorectal cancer establishes Tenascin-C as a stromal biomarker for colorectal cancer metastasis. Oncotarget (2016) 0.81
Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue. Virology (2013) 0.80
S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. Br J Cancer (2015) 0.79
Lung Pericytes and Resident Fibroblasts: Busy Multitaskers. Am J Pathol (2016) 0.79
Antitumor effects of calgranulin B internalized in human colon cancer cells. Oncotarget (2016) 0.78
Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways. BMC Cancer (2016) 0.78
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget (2014) 0.77
Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res (2015) 0.76
Dissecting characteristics and dynamics of differentially expressed proteins during multistage carcinogenesis of human colorectal cancer. World J Gastroenterol (2016) 0.76
Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. Immunol Cell Biol (2013) 0.76
Cerebrospinal fluid biomarker candidates associated with human WNV neuroinvasive disease. PLoS One (2014) 0.76
Annexin A1 can inhibit the in vitro invasive ability of nasopharyngeal carcinoma cells possibly through Annexin A1/S100A9/Vimentin interaction. PLoS One (2017) 0.75
S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine. Sci Rep (2016) 0.75
Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. Oncoimmunology (2016) 0.75
CD8+ T cells produce a dialyzable antigen-specific activator of dendritic cells. J Leukoc Biol (2016) 0.75
Proteins that interact with calgranulin B in the human colon cancer cell line HCT-116. Oncotarget (2016) 0.75
Is calprotectin a novel biomarker of neuroinflammation in diabetic periferal neuropathy? Diabetol Metab Syndr (2015) 0.75
Calprotectin in rheumatic diseases. Exp Biol Med (Maywood) (2016) 0.75
The HPV16 E7 Oncoprotein Disrupts Dendritic Cell Function and Induces the Systemic Expansion of CD11b(+)Gr1(+) Cells in a Transgenic Mouse Model. Biomed Res Int (2016) 0.75
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
TGFbeta signaling in growth control, cancer, and heritable disorders. Cell (2000) 12.38
Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol (2006) 5.82
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med (2007) 5.47
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 5.23
A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun (1965) 4.22
S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol (2006) 4.20
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol (2008) 3.91
S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol (2006) 3.67
Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature (1987) 3.12
The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol (2009) 3.01
The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol (2010) 2.94
Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol (2003) 2.59
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol (2005) 2.41
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem (1991) 2.07
S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech (2003) 1.99
S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res (2011) 1.98
S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res (2005) 1.95
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother (2011) 1.94
MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. J Leukoc Biol (1993) 1.92
Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology (2005) 1.82
Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res (2002) 1.81
Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res (2005) 1.81
Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene (2004) 1.77
The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem (2001) 1.72
MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood (2004) 1.71
The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther (2006) 1.67
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol (2009) 1.65
Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol (1988) 1.64
S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem (2003) 1.58
S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem (2005) 1.52
Calcium-dependent complex assembly of the myeloic differentiation proteins MRP-8 and MRP-14. J Biol Chem (1991) 1.51
MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol (2009) 1.51
Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J Mol Biol (2006) 1.46
Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol (2006) 1.40
The two calcium-binding proteins, S100A8 and S100A9, are involved in the metabolism of arachidonic acid in human neutrophils. J Biol Chem (1999) 1.39
The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J (2005) 1.39
Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim Biophys Acta (1998) 1.39
Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem (2004) 1.38
S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets (2008) 1.37
Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochim Biophys Acta (2006) 1.30
A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol (1999) 1.29
S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology (2009) 1.28
Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J Immunol (2006) 1.27
S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem (1999) 1.24
Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res (2009) 1.24
Inflammatory cells in the formation of tumor-related sarcoid reactions. Hum Pathol (2005) 1.24
S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun (2011) 1.20
Interaction of S100A8/S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry (2001) 1.19
Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res (2007) 1.18
Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res (2008) 1.17
The crystal structure of human MRP14 (S100A9), a Ca(2+)-dependent regulator protein in inflammatory process. J Mol Biol (2002) 1.17
Carboxylated glycans mediate colitis through activation of NF-kappa B. J Immunol (2005) 1.12
S-nitrosylated S100A8: novel anti-inflammatory properties. J Immunol (2008) 1.12
Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res (2006) 1.12
Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer (2006) 1.11
The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis (1999) 1.10
Oxidation of methionine 63 and 83 regulates the effect of S100A9 on the migration of neutrophils in vitro. J Leukoc Biol (2006) 1.10
HaCaT keratinocytes overexpressing the S100 proteins S100A8 and S100A9 show increased NADPH oxidase and NF-kappaB activities. J Invest Dermatol (2007) 1.09
Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep (2009) 1.09
Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leukoc Biol (1995) 1.06
Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol (2004) 1.06
The heterodimeric complex of MRP-8 (S100A8) and MRP-14 (S100A9). Antibody recognition, epitope definition and the implications for structure. Eur J Biochem (2001) 1.05
Induction of S100A9 gene expression by cytokine oncostatin M in breast cancer cells through the STAT3 signaling cascade. Breast Cancer Res Treat (2004) 1.05
An update of the S100 nomenclature. Biochim Biophys Acta (2006) 1.05
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics (2008) 1.04
Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics (2001) 1.04
Zinc replenishment reverses overexpression of the proinflammatory mediator S100A8 and esophageal preneoplasia in the rat. Gastroenterology (2008) 1.02
Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncol Rep (2001) 1.01
The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLoS One (2011) 1.01
S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer (2004) 1.01
Relating form and function of EF-hand calcium binding proteins. Acc Chem Res (2011) 0.99
Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol Pathol (2001) 0.99
Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res (2008) 0.99
Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol (2000) 0.98
Phosphorylation of myeloid-related proteins MRP-14 and MRP-8 during human neutrophil activation. Eur J Biochem (1996) 0.97
Expression of MRP14 gene is frequently down-regulated in Chinese human esophageal cancer. Cell Res (2004) 0.97
Macrophage/microglial cell subpopulations in glioblastoma multiforme relapses are differentially altered by radiochemotherapy. J Neurooncol (2001) 0.97
A novel p53 target gene, S100A9, induces p53-dependent cellular apoptosis and mediates the p53 apoptosis pathway. Biochem J (2009) 0.96
Increase of calcium levels in epithelial cells induces translocation of calcium-binding proteins migration inhibitory factor-related protein 8 (MRP8) and MRP14 to keratin intermediate filaments. Biochem J (1995) 0.96
The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics (2007) 0.94
Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate (2011) 0.94
Gene expression profile and genomic alterations in colonic tumours induced by 1,2-dimethylhydrazine (DMH) in rats. BMC Cancer (2010) 0.94
S-glutathionylation regulates inflammatory activities of S100A9. J Biol Chem (2010) 0.93
Biochemical characterization of the murine S100A9 (MRP14) protein suggests that it is functionally equivalent to its human counterpart despite its low degree of sequence homology. Eur J Biochem (2000) 0.93
Zinc binding reverses the calcium-induced arachidonic acid-binding capacity of the S100A8/A9 protein complex. FEBS Lett (1999) 0.93
Protein abundance alterations in matched sets of macroscopically normal colon mucosa and colorectal carcinoma. Electrophoresis (1999) 0.93
Purification and characterization of the cytotoxic factor in rat peritoneal exudate cells: its identification as the calcium binding protein complex, calprotectin. J Leukoc Biol (1995) 0.91
The hetero-oligomeric complex of the S100A8/S100A9 protein is extremely protease resistant. FEBS Lett (2007) 0.90
Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett (2006) 0.89
Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol (2008) 0.89
Binding of two nuclear complexes to a novel regulatory element within the human S100A9 promoter drives the S100A9 gene expression. J Biol Chem (2002) 0.88
Quantitative proteomic analysis of differential proteins in the stroma of nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissue. J Cell Biochem (2009) 0.87
Defective chemoattractant-induced calcium signalling in S100A9 null neutrophils. Cell Calcium (2006) 0.86
Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer (2008) 3.68
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol (2004) 2.55
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. Clin Cancer Res (2010) 1.76
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest (2002) 1.74
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood (2004) 1.73
Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature. World J Surg Oncol (2008) 1.73
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res (2007) 1.66
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res (2011) 1.61
Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun (2007) 1.59
Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol (2006) 1.58
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res (2004) 1.55
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther (2009) 1.54
β-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption. Brain Behav Immun (2012) 1.50
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother (2011) 1.47
Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44
Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst (2004) 1.42
Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS One (2007) 1.36
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res (2006) 1.32
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer (2010) 1.27
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood (2008) 1.26
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol (2011) 1.25
IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol (2007) 1.23
A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med (2009) 1.22
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat (2008) 1.21
Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun (2006) 1.18
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest (2003) 1.17
Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res (2007) 1.16
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol (2005) 1.15
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res (2008) 1.11
Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. Cancer Immunol Immunother (2008) 1.08
Melanoma, version 4.2014. J Natl Compr Canc Netw (2014) 1.07
Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology (2012) 1.05
Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat (2013) 1.04
Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol (2011) 1.03
STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha. Cancer Immunol Immunother (2007) 1.03
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.02
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res (2002) 1.02
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol (2009) 1.02
Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. Clin Cancer Res (2008) 1.02
Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol (2012) 1.01
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res (2006) 1.00
Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol (2006) 0.99
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother (2014) 0.97
IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J Immunol (2004) 0.97
Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother (2005) 0.96
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin Cancer Res (2010) 0.96
Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery (2012) 0.95
Delayed emotional recovery after taxane-based chemotherapy. Cancer (2008) 0.93
Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res (2007) 0.93
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother (2011) 0.93
Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain Behav Immun (2011) 0.93
Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12. Cancer Res (2005) 0.93
Re-emphasizing the concept of adequacy of intraoperative assessment of the axillary sentinel lymph nodes for identifying nodal positivity during breast cancer surgery. World J Surg Oncol (2007) 0.92
Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer. Health Psychol (2011) 0.92
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A (2014) 0.91
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol (2005) 0.90
Melanoma. J Natl Compr Canc Netw (2012) 0.90
Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. J Immunother (2012) 0.90
FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. Blood (2006) 0.89
Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Exp Eye Res (2012) 0.89
Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer (2010) 0.88
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther (2010) 0.88
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol (2003) 0.87
VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res (2008) 0.87
NK cell-based immunotherapy for treating cancer: will it be promising? Korean J Hematol (2011) 0.87
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay. Cancer Immunol Immunother (2008) 0.85
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother (2005) 0.84
Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells. Cancer Immunol Immunother (2011) 0.84
IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2. Clin Cancer Res (2008) 0.84
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother (2014) 0.84
Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment. J Control Release (2011) 0.83
Immune modulation with interleukin-21. Ann N Y Acad Sci (2009) 0.82
Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects. Surgery (2006) 0.82
Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann Surg Oncol (2003) 0.82
Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta. Arthritis Res Ther (2013) 0.82
Impact of breast cancer recurrence and cancer-specific stress on spouse health and immune function. Brain Behav Immun (2011) 0.81
Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy. World J Surg Oncol (2008) 0.81
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. J Immunother (2014) 0.80
Heparin-binding EGF-like growth factor (HB-EGF) protects the intestines from radiation therapy-induced intestinal injury. J Pediatr Surg (2013) 0.80
The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. Am J Transl Res (2013) 0.80
A pilot study of bevacizumab and interferon-α2b in ocular melanoma. Am J Clin Oncol (2011) 0.79
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells. Cancer Immunol Immunother (2009) 0.79
Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. Radiology (2013) 0.79
Review of complementary and alternative medicine and selected nutraceuticals: background for a pilot study on nutrigenomic intervention in patients with advanced cancer. Altern Ther Health Med (2012) 0.78
Folate-immunoglobulin G as an anticancer therapeutic antibody. Bioconjug Chem (2010) 0.78
Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed Microdevices (2005) 0.78
Cognitive problems among breast cancer survivors: loneliness enhances risk. Psychooncology (2014) 0.77
Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells. Vet Immunol Immunopathol (2013) 0.77
Novel cytokines in the treatment of malignancies. Cancer Treat Res (2005) 0.76
Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions. Melanoma Res (2016) 0.75
Getting melanoma cells to stimulate with frequency. J Clin Oncol (2005) 0.75
Individualized local treatment strategies for in-transit melanoma. Oncology (Williston Park) (2011) 0.75
Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010. J Immunother (2010) 0.75
A naonoporous cell-therapy device with controllable biodegradation for long-term drug release. J Control Release (2012) 0.75
Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma. Cancer Immunol Immunother (2002) 0.75